Autopsy report · NCT00773552

Solifenacin Succinate Versus Placebo in Inner City Women Ages 20-45 With Overactive Bladder

“Investigator Left Institution”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 4

Sponsor

Stamford Hospital

Sponsor type

University, hospital or other

Conditions

Urinary Urge; Urge Incontinence; Overactive Bladder

Interventions

solifenacin succinate; placebo

Participants

0

Sites

2

Countries

United States

Trials that died the same way

• Intralesional Tetracycline Injection in the Treatment of Chalazia
  “Investigator left the institution” (96% match in meaning)
• Study of Antibiotics in Cerebrospinal Fluid Following Intravenous Injection
  “Primary investigator left institution” (94% match in meaning)
• Pilot Study of the Effect of Topical Bromfenac Ophthalmic Solution 0.09%in Patients With Acute Post-operative Cystoid Macular Edema.
  “Principal Investigator left institution” (93% match in meaning)
• Opioid Induced Loss of Local Anesthetic Potency in Patients Undergoing Total Knee Arthroplasty
  “Responsible Investigator left institution” (93% match in meaning)
• Individualized Repetitive Transcranial Magnetic Stimulation for Auditory Verbal Hallucinations
  “Investigator departed from institution” (91% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.